Safety and clinical activity of combined PD-1 (nivolumab) and CTLA-4 (ipilimumab) blockade in advanced melanoma patients

By J. Wolchok, H. Kluger, M. Callahan, M. Postow, N. Rizvi, A. Lesokhin, N. Segal, C. Ariyan, R. Gordon, Kathleen Reed and 14 more. New England Journal of Medicine, 2013

3,871 citations recorded by the source corpus.

Background In patients with melanoma, ipilimumab (anti-CTLA-4) prolongs overall survival and nivolumab (anti-PD-1) produced durable tumor regressions in a phase 1 trial. Based on their distinct immunologic mechanisms of action and supportive preclinical data, we conducted a phase 1 trial of nivolumab combined with ipilimumab in advanced melanoma patients. Methods Patients received nivolumab and ipilimumab every 3 weeks for 4 doses, followed by nivolumab alone every 3 weeks for 4 doses (concurrent regimen). Combined treatment was subsequently continued every 12 weeks for up to 8 doses. In a sequenced regimen, patients previously treated with ipilimumab received nivolumab every 2 weeks. Results Fifty-three patients received concurrent nivolumab/ipilimumab and 33 received sequenced treatment. The objective response rate, for all concurrent-regimen patients was 40% (modified WHO criteria). Evidence of clinical activity (conventional, unconfirmed, or immune-related response or stable disease ≥24 weeks) was observed in 65% of patients. At the maximum tolerated dose (1 mg/kg nivolumab + 3 mg/kg ipilimumab), 53% of patients achieved an objective response, all with ≥80% tumor reduction. Grade 3–4 related adverse events occurred in 53% of concurrent-regimen patients, but were qualitatively similar to historical monotherapy experience and were generally reversible. Among sequenced-regimen patients, 18% had grade 3–4 related adverse events and the objective response rate was 20%. Conclusions Concurrent nivolumab/ipilimumab had a manageable safety profile and achieved clinical activity that is distinct from published monotherapy data, with rapid and deep tumor regressions in a substantial number of patients.

Subfields: Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/52da7bf4540f850d9ab345f8c2f61b125e2a57d7

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

In Oncology

Citations in the corpus

Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis (2017, background): “001) (Figure 2).(14-50) The predicted incidence of hypothyroidism ranged from 3.”
Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes (2015, background): “Recent trials of concurrent anti–CTLA-4 and anti–PD-1 therapies showed an impressive ORR of over 50% with long duration of response, and superior progression-free survival (PFS) to ipilimumab alone, but grade III/IV irAEs occurred in over 50% of patients in the concurrent-regimen group (12, 13).”
Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade (2017, positive): “It is likely that dual engagement of these distinct cellular mechanisms underlies, at least in part, the enhanced efficacy of combination anti-CTLA-4 and anti-PD-1 therapy that has been observed in preclinical and clinical contexts (Curran et al., 2010; Wolchok et al., 2013).”
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic (2018, background): “advanced melanoma, non-small cell lung cancer (NSCLC), urothelial cancer (UC), renal cell carcinoma (RCC), and other cancer types [1-8].”
From chemotherapy to biological therapy: A review of novel concepts to reduce the side effects of systemic cancer treatment (Review) (2018, neutral): “The side effects of these two approaches, however, were different: Grade 0-2 for the vaccination study compared with grade 1-4 for the ICB study.”
PD-L1 expression in human cancers and its association with clinical outcomes (2016, neutral): “Therefore, using tumor PD-L1 expression as exclusionary predictive biomarker for the outcome of PD-1/PD-L1 blockade therapy has its limitations.(47) mAbs targeting PD-1/PD-L1 pathway have achieved impressive response rates in patients with melanoma, NSCLC, RCC, and bladder cancer, and the value of P”